

County Council of Howard County, Maryland

2016 Legislative Session

Legislative day # 2

RESOLUTION NO. 16 - 2016

Introduced by: Chairperson at the request of the County Executive

A RESOLUTION confirming the appointment of Ivan Montoya to the Alcohol & Drug Abuse Advisory Board.

Introduced and read first time on February 1, 2016.

By order Jessica Feldmark
Jessica Feldmark, Administrator to the County Council

Read for a second time and a public hearing held on February 16, 2016.

By order Jessica Feldmark
Jessica Feldmark, Administrator to the County Council

This Resolution was read the third time and was Adopted , Adopted with amendments , Failed , Withdrawn by the County Council on March 7, 2016.

Certified by Jessica Feldmark
Jessica Feldmark, Administrator to the County Council

NOTE: [[text in brackets]] indicates deletions from existing language; TEXT IN SMALL CAPITALS indicates additions to existing language. Strike-out indicates material deleted by amendment; Underlining indicates material added by amendment.

Iván D. Montoya, M.D., M.P.H.

Curriculum Vitae

Current Position

Deputy Director,
Division of Therapeutics and Medical Consequences (DPMC)
National Institute on Drug Abuse (NIDA)

Education

1988-1990	Masters in Public Health The Johns Hopkins School of Public Health
1986-1990	Residency in Psychiatry 1986-1990 University of Antioquia (Colombia)
1974-1982	Doctor in Medicine and Surgery University of Antioquia. Medellín, Colombia.
1962-1973	Elementary and High School. San José de Calasanz School. Medellín, Colombia.

Employment History

2008 - Present	Deputy Director , DPMC, NIDA
2012 – 2015	Chair , Institutional Review Board, NIDA & NIAAA.
1999 - 2003	Medical Officer , DPMC, NIDA (Bethesda, MD)
1998 - 1999	Director , Practice Research Network. American Psychiatric Association (Washington DC)
1997 - 1999	Consultant . World Health Organization (Washington, DC)
1995 - 1999	Associate Professor . University of Antioquia (Colombia)
1989 - 1995	Visiting Fellow . NIDA-IRP (Baltimore, MD)
1985 - 1988	Director . Occupational Medicine Department, City of Medellin
1984 - 1985	Director . Family Medicine Department, City of Medellin
1982 - 1983	Director . Arboletes Hospital (Colombia).

PUBLICATIONS

1. Gorelick, D.A.; Covi, L.; **Montoya, I.D.**; Hess, M.A.: Sociodemographic Factors in Drug Abuse Treatment. *Journal of Addictive Diseases*, 11(2):175. 1992.
2. Greberman, S.B.; **Montoya, I.D.**; Ball, J.C.: National Substance Abuse Databases. *MEDINFO 92* / Lun, K.C. et al. (editors). Elsevier Science Publishers B.V. (Holland) pp. 408. 1992.
3. **Montoya, I.D.**; Hess, J.M.; Covi, L.; Fudala, P.J.; Johnson, R.E.: A Comparative Study of Psychopathology and Cognitive Functions between Cocaine and Opiate Dependent Patients Seeking Treatment. *American Journal on Addictions*, 3(1):36-42. 1994.
4. **Montoya, I.D.**; Haertzen, C.A.: Reduction of Psychopathology Among Individuals Participating in Non-treatment Drug Abuse Residential Studies. *Journal of Addictive Diseases*, 13(2):89-97. 1994 (Winner of the 1995 Young Investigator Award).
5. Mandell, W.; **Montoya, I.D.**; Hardy, J.: International, Multidisciplinary Training in Substance Abuse: An Essential Tool for Prevention. *Substance Abuse*, 15(1):21-27. 1994.
6. **Montoya, I.D.**, Haertzen, C., Hess, J.M., Covi, L., Fudala, P.J., Johnson, R.E., Gorelick, D.A.: Comparison of Psychological Symptoms between Treatment-seeking and Non-treatment Seeking Drug Abusers. *Journal of Nervous and Mental Disease*, 183(1):50-53. 1995.
7. **Montoya, I.D.**, Levin, F.R., Fudala, P.J. Gorelick, D.A.: A Double-Blind Comparison of Carbamazepine and Placebo for Treatment of Cocaine Dependence. *Drug and Alcohol Dependence*, 38:213-219, 1995.
8. **Montoya, I.D.**, Hess, J.M., Preston, K., Gorelick, D.A.: A Model for Outpatient Treatment Research of Cocaine Dependence at the NIDA-ARC. *Journal of Substance Abuse Treatment*, 12(6):415-421, 1995.
9. **Montoya, I.D.**, Preston, K., Rothman, R., Gorelick, D.A.: Safety and efficacy of the Combination of Bupropion and Bromocriptine for Treatment of Cocaine Dependence. *American Journal on Addictions*, 5:69-75, 1996.
10. **Montoya, I.D.**, Chilcoat, H.: Epidemiology of Coca and Derivatives Use in the Andean Region: A Tale of 5 Countries. *Substance Use and Misuse*: 31(10):1227-1240, 1996.
11. Jenkins, A., **Montoya, I.D.**, Llosa, T., Cone, E.: Identification and Quantitation of Alkaloids in Coca Tea. *Forensic Science International* 77:179-189, 1996.

12. Silverman, K., Higgins, S.T., Brooner, R.K., **Montoya, I.D.**, Schuster, C.R., Preston, K.P.: Contingency management of cocaine use in a methadone maintenance program. *Archives of General Psychiatry* 53(5): 409-415. 1996.
13. Silverman, K., Wong, C., Higgins, S., Brooner, R., **Montoya, I.D.**, Contoreggi, C., Umbricht, A., Schuster, C., Preston, K.: Increasing opiate abstinence through voucher-based reinforcement therapy. *Drug and Alcohol Dependence* 41(2): 157-165. 1996.
14. Gorelick, D.A., **Montoya, I.D.**: Sociodemographic Groups in Cocaine Pharmacotherapy Studies. *Drug and Alcohol Dependence*. 49(2): 89-93. 1998.
15. Brook, J.S., Brook, D.W., de la Rosa, M., Duque, L.F., Rodriguez, E., **Montoya, I.D.**, Whiteman, M.: Pathways to Marijuana Use Among Adolescents: Cultural/Ecological, Family, Peer, and Personality Influences. *Journal of the American Academy of Child and Adolescent Psychiatry* 37(7):759-766. 1998.
16. Preston, K., Silverman, K., Brooner, R.K., Umbricht-Schneiter, A., **Montoya, I.D.**, Cone, E.J., Schuster, C.R., Higgins, S.: Cocaine Use Early in Treatment Predicts Outcome in a Behavioral Treatment Program. *Journal of Consulting and Clinical Psychology*. 1998 Aug;66(4):691-6.
17. Silverman, K., Wong, C., Umbricht-Schneiter, A., **Montoya, I.D.**, Schuster, C.R., Preston, K.: Broad Beneficial Effects of Cocaine Abstinence Reinforcement in Methadone Patients. *Journal of Consulting and Clinical Psychology* 1998 Oct; 66(5):811-24.
18. Preston, K., Silverman, K., Umbricht-Schneiter, Anna DeJesus, A., **Montoya, I.D.**, Schuster, C.R.: Improvement in Naltrexone Treatment Compliance with Contingency Management. *Drug and Alcohol Dependence*. 1999 Apr 1;54(2):127-35.
19. Brook, D.W., Brook, J.S., De la Rosa, M., **Montoya, I.D.**, Whiteman, M., Jaeger, L.: The Role of Parents in Protecting Colombian Adolescents from Delinquency and Drug Use. *Archives of Pediatrics and Adolescent Medicine*. 1999 May;153(5):457-64.
20. Aszalos R., McDuff, D., **Montoya, I.D.**, Johnson, J., Weintraub, E., Schwartz, R.: Engaging hospitalized heroin-dependent patients into substance abuse treatment. *Journal of Substance Abuse Treatment*. 1999 Jul-Sep;17(1-2):149-58 (ASAM Young Investigator Award).
21. Umbricht-Schneiter, A., **Montoya, I.D.**, Hoover, D.R., Demuth, K.L., Chiang, C.T., Preston, K.: Naltrexone shortened opioid detoxification with buprenorphine. *Drug Alcohol Depend*. 1999 Oct 1;56(3):181-90.
22. Hall GW, Carriero NJ, Takushi RY, **Montoya ID**, Preston KL, Gorelick DA.

Pathological gambling among cocaine-dependent outpatients. *Am J Psychiatry*. 2000 Jul;157(7):1127-33.

23. Schwartz RP, Brooner RK, **Montoya ID**, Currens M, Hayes M: A 12-year follow-up of a methadone medical maintenance program. *Am J Addict*. 1999 Fall;8(4):293-9.
24. **Montoya I.D.**, Svikis D., Marcus S., Suarez, A., Tanielian, T., Pincus, H.A.: Psychiatric Care of Patients with Depression and Co-morbid Substance Use Disorders. *Journal of Clinical Psychiatry*. 2000 Sep;61(9):698-705; quiz 706.
25. Escobar, R., Rios, A., **Montoya, I.D.**, Ramos, D., Carvajal, C., Constain, G., Gutiérrez, J.E. Vargas, S.: Clinical And Cerebral Blood Flow Changes In Catatonic Patients Treated With ECT. *Journal of Psychosomatic Research*. 2000 Dec;49(6):423-9.
26. Brook JS, Brook DW, De La Rosa M, Whiteman M, Johnson E, **Montoya ID**.: Adolescent illegal drug use: the impact of personality, family, and environmental factors. *J Behav Med*. 2001 Apr;24(2):183-203.
27. **Montoya, I.D.**, Carriero, N., Preston, K.L., Gorelick D.: Open-label pilot study of bupropion plus bromocriptine for treatment of cocaine dependence. *The American Journal of Drug and Alcohol Abuse* (2002) 28(1), 189-196
28. DiPaula, B., **Montoya I.D.**, Schwartz, R.: Buprenorphine treatment for dually diagnosed patients. *Journal of Substance Abuse Treatment*. 2002 Oct;23(3):163-169.
29. Brook, D.W., Brook, J.S., Pahl, T., **Montoya, I.D.**: The Longitudinal Relationship Between Drug Use and Risky Sexual Behaviors among Colombian Adolescents. *Archives of Pediatrics and Adolescent Medicine*. 2002 Nov;156(11):1101-7.
30. Brook DW, Brook JS, Rosen Z, **Montoya ID**: Correlates of marijuana use in Colombian adolescents: a focus on the impact of the ecological/cultural domain. *J Adolesc Health*. 2002 Sep;31(3):286-98.
31. **Montoya, ID**, Herbeck D, Svikis DS, Fitek DJ, Marcus, SC: Practice Patterns of Psychiatrists Who Treat Patients with Substance Use Disorders. *Am J Addict*. 2003 May-Jun;12(3):181-92.
32. Brook DW, Brook JS, Rosen Z, De La Rosa M, **Montoya ID**, Whiteman M.: Early risk factors for violence in Colombian adolescents. *Am J Psychiatry*. 2003 Aug;160(8):1470-8.
33. **Montoya, I.D.**, Gorelick, D., Preston, K., Umbricht-Schneiter, A., Cheskin, L., Contoreggi, C., Johnson, R.E., Fudala, P.: Buprenorphine for Treatment of Dually-Dependent (Opiate and Cocaine) Individuals. *Clinical Pharmacology and*

Therapeutics. 75(1):34-48 2004

34. Forman R, Svikis D, **Montoya ID**, Blaine J: Selection of a Substance Use Disorder Diagnostic Instrument by the National Drug Abuse Treatment Clinical Trials Network. *Journal of Substance Abuse Treatment* 2004 Jul;27(1):1-8.
35. Velez ML, Jansson LM, **Montoya ID**, Schweitzer W, Golden A, Svikis D. Parenting knowledge among substance abusing women in treatment. *J Subst Abuse Treat*. 2004 Oct;27(3):215-22.
36. Herbeck DM, Fitek DJ, Svikis DS, **Montoya ID**, Marcus SC, West JC: Treatment compliance in patients with comorbid psychiatric and substance use disorders. *Am J Addict*. 2005 May-Jun;14(3):195-207.
37. **Montoya ID**, Schroeder JR, Preston KL, Covi L, Umbricht A, Contoreggi C, Fudala PJ, Johnson RE, Gorelick DA. Influence of psychotherapy attendance on buprenorphine treatment outcome. *J Subst Abuse Treat*. 2005 Apr;28(3):247-54.
38. Levav, I, Kohn R, **Montoya ID**, Palacio C, Rozic P, Solano I, Valentini W, Vicente B, Castro J, Espejo F, Saravan Y, Miranda C, Sartorius N: Training Latin American Primary Care Physicians in the WPA Module of Depression: Results of a Multicenter Trial. *Psychological Medicine*, 2005, 35, 35-45.
39. Ziedonis, DM; Smeison, D; Rosenthal, RN; Batkil, SL; Green, AI; Henry, RJ; **Montoya, ID**; Parks, J; Weiss, RD: Improving the Care of Individuals with Schizophrenia and Substance Use Disorders: Consensus Recommendations. *Journal of Psychiatric Practice*, 11(5):315-39. 2005
40. **Montoya ID**, Herbeck DM, Svikis DS, Pincus HA: Identification and Treatment of Patients with Nicotine Problems in Routine Clinical Psychiatry Practice. *American Journal on Addictions*. 14(5):441-54. 2005.
41. Velez, M. L., **Montoya, I. D.**, Jansson, L. M., Walters, V., Svikis, D., Jones, H. E. et al.. Exposure to violence among substance-dependent pregnant women and their children. *J.Subst.Abuse Treat.*, 30, 31-38. 2006
42. **Montoya ID**, Vocci F: Future Perspectives of Pharmacotherapies for Nicotine Dependence. In George T.: Medication Treatments for Nicotine Dependence. Taylor Francis publisher. Pp 293-303. 2006.
43. Conway, K, **Montoya, I. D.**, Compton, W: Comorbidity of Substance Use Disorders and other Psychiatric Disorders. *Psychiatric Times*. Vol 24 (4). April 2007
44. **Montoya, I.D.**; Vocci, F.: Medications Development for the Treatment of Nicotine Dependence in Individuals with Schizophrenia. *Journal of Dual Diagnosis*. Vol. 3 (3-4): 113-150, 2007

45. Ziedonis, D.; **Montoya, I.D.**: Nicotine Dependence and Schizophrenia. *Journal of Dual Diagnosis*. Journal of Dual Diagnosis. Vol. 3 (3-4): 3-7, 2007
46. **Montoya ID**, Vocci F. Novel medications to treat addictive disorders. *Curr Psychiatry Rep*. 2008;10:392-98.
47. **Montoya ID**. Immunotherapies for drug addictions. *Adicciones*.;20:111-15. 2008
48. Yu, E., Miotto, K., Akerele, E., Montgomery, A., Elkashef, A., Walsh, R., **Montoya, I.**, Fischman, M. W., Collins, J., McSherry, F., Boardman, K., Davies, D. K., O'Brien, C. P., Ling, W., Kleber, H., and Herman, B. H.: A Phase 3 Placebo-Controlled, Double-Blind, Multi-Site Trial of the Alpha-2-Adrenergic Agonist, Lofexidine, for Opioid Withdrawal. *Drug Alcohol Depend*. 97(1-2):158-68. 2008
49. Kahn, R., Biswas, K., Childress, A. R., Shoptaw, S., Fudala, P. J., Gorgon, L., **Montoya, I.**, Collins, J., McSherry, F., Li, S. H., Chiang, N., Alathari, H., Watson, D., Liberto, J., Beresford, T., Stock, C., Wallace, C., Gruber, V., and Elkashef, A.. Multi-Center Trial of Baclofen for Abstinence Initiation in Severe Cocaine-Dependent Individuals. *Drug Alcohol Depend*. 103(1-2):59-64. 2009
50. Vocci FJ, **Montoya ID**. Psychological treatments for stimulant misuse, comparing and contrasting those for amphetamine dependence and those for cocaine dependence. *Curr Opin Psychiatry*.22:263-68. 2009
51. Drgon T, **Montoya ID**, Johnson C, Liu QR, Walther D, Hamer D et al. Genome-wide association for nicotine dependence and smoking cessation success in NIH research volunteers. *Mol Med*.15:21-27. 2009
52. Hitsman B, Moss TG, **Montoya ID**, George TP.: Treatment of tobacco dependence in mental health and addictive disorders. *Can J Psychiatry*. 2009 Jun;54(6):368-78.
53. **Montoya ID**, McCann D: Drugs of Abuse: Management of Intoxication and Antidotes. In: *Textbook of Toxicology: Molecular, Clinical and Environmental Toxicology*. Volume 2: Clinical Toxicology. EXS. 2010;100:519-41.
54. Okuda M, Hasin DS, Olfson M, Khan SS, Nunes EV, **Montoya I**, Liu SM, Grant BF, Blanco C.: Generalizability of clinical trials for cannabis dependence to community samples. *Drug Alcohol Depend*. 2010 Sep 1;111(1-2):177-81.
55. Harrell PT, **Montoya ID**, Preston KL, Juliano LM, Gorelick DA.: Cigarette smoking and short-term addiction treatment outcome. *Drug Alcohol Depend*. 2010 Dec 14.
56. Kahn R, Gorgon L, Jones K, McSherry F, Glover ED, Anthenelli RM, Jackson T, Williams J, Murtaugh C, **Montoya I**, Yu E, Elkashef A. Selegiline Transdermal System (STS) as an Aid for Smoking Cessation. *Nicotine Tob Res*. 2012 Mar;14(3):377-82.

57. **Montoya I.D.:** Advances in the development of biologics to treat drug addictions and overdose. *Adicciones*. 2012;24(2):95-103.
58. Elkashef A, **Montoya ID:** Pharmacotherapy of Addiction. In: *Drug Abuse and Addiction in Medical Illness*. Verster JC, Brady K, Galanter M, Conrod P Editors. Springer, New York. 2012 pps: 107-119.
59. **Montoya, ID:** Smoking and Cocaine Use. In: Muller, F & Serebrisky D: *Smoking and Psychiatric Illness: Tools for Action*. Buenos Aires. Editorial Sciens. October 2012. p. 165-178
60. Smith SM, Dart RC, Katz NP, Paillard F, Adams EH, Comer SD, Degroot A, Edwards RR, David Haddox J, Jaffe JH, Jones CM, Kleber HD, Kopecy EA, Markman JD, **Montoya ID**, O'Brien C, Roland CL, Stanton M, Strain EC, Vorsanger G, Wasan AD, Weiss RD, Turk DC, Dworkin RH. Classification and definition of misuse, abuse, and related events in clinical trials: ACTION systematic review and recommendations. *Pain*. 013 Nov;154(11):2287-96

Ivan D. Montoya, M.D., M.P.H.

Dr. Montoya is the Deputy Director of the Division of Pharmacotherapies and Medical Consequences (DPMC) and Senior Medical Officer at the National Institute on Drug Abuse (NIDA). He received an M.D. from the University of Antioquia (Colombia), a Masters in Public Health from The Johns Hopkins School of Public Health, and completed residency training in Psychiatry at the University of Antioquia and the University of Maryland Hospital (Baltimore). He was a Fulbright-Hubert H. Humphrey Fellow at The Johns Hopkins School of Public Health, Visiting Foreign Fellow at the Intramural Research Program of NIDA, Director of the Practice Research Network of the American Psychiatric Association, and consultant for the World Health Organization's Pan American Health Organization. He has published extensively in the areas of etiology, prevention, treatment (pharmacological and non-pharmacological), and medical consequences of drug abuse.